Substantial Impact of Post Vaccination Contacts on Cumulative Infections during Viral Epidemics

4	Nash D. Rochman ^{1,*} , Yuri I. Wolf ¹ , and Eugene V. Koonin ^{1,*}
5	¹ National Center for Biotechnology Information, National Library of Medicine, Bethesda, MD 20894
6	
7	For correspondence: <u>nash.rochman@nih.gov</u> , <u>koonin@ncbi.nlm.nih.gov</u>
8	
9	Keywords: SARS-CoV-2, Vaccine Escape, Vaccine Resistance, compartment model
10	
11	

It is made available under a CC-BY-NC-ND 4.0 International license .

12 Abstract:

13

Background: The start of 2021 will be marked by a global vaccination campaign 14 against the novel coronavirus SARS-CoV-2. Formulating an optimal distribution strategy 15 under social and economic constraints is challenging. Optimal distribution is additionally 16 constrained by the potential emergence of vaccine resistance. Analogous to chronic 17 low-dose antibiotic exposure, recently inoculated individuals who are not yet immune 18 19 play an outsized role in the emergence of resistance. Classical epidemiological modelling is well suited to explore how the behavior of the inoculated population 20 impacts the total number of infections over the entirety of an epidemic. 21 Methods: A deterministic model of epidemic evolution is analyzed, with 7 22 23 compartments defined by their relationship to the emergence of vaccine-resistant mutants and representing three susceptible populations, three infected populations, and 24 25 one recovered population. This minimally computationally intensive design enables simulation of epidemics across a broad parameter space. The results are used to 26 27 identify conditions minimizing the cumulative number of infections. **Results:** When an escape variant is only modestly less infectious than the originating 28 strain within a naïve population, there exists an optimal rate of vaccine distribution. 29 Exceeding this rate increases the cumulative number of infections due to vaccine 30 escape. Analysis of the model also demonstrates that inoculated individuals play a 31 32 major role in the mitigation or exacerbation of vaccine-resistant outbreaks. Modulating the rate of host-host contact for the inoculated population by less than an order of 33 magnitude can alter the cumulative number of infections by more than 20%. 34 **Conclusions:** Mathematical modeling shows that optimization of the vaccination rate 35 and limiting post-vaccination contacts can affect the course of an epidemic. Given the 36 relatively short window between inoculation and the acquisition of immunity, these 37 38 results might merit consideration for an immediate, practical public health response. 39

It is made available under a CC-BY-NC-ND 4.0 International license .

40 Introduction:

41

The emergence of the novel Severe Acute Respiratory Syndrome Coronavirus 2 42 43 (SARS-CoV-2) responsible for the Covid-19 pandemic motivated dramatic public health intervention including recommendations for isolation and guarantine throughout most of 44 2020¹. The beginning of 2021 will be marked by widespread vaccine distribution. 45 Optimizing distribution is challenging and subject to a myriad of social and economic 46 47 constraints²⁻⁴. The potential emergence of vaccine-resistant variants of the virus^{5,6} introduces additional complications. Vaccination applies new selective pressures which 48 49 can lead to diverse intermediate outcomes even under conditions admitting eventual pathogen eradication⁷⁻¹³. The larger the size of the vaccinated population, the greater 50 the pressure towards escape of vaccine-resistant variants. 51

52

Escape variants emerge within individual hosts after infection with the originating strain. 53 Naïve, unvaccinated, hosts are more easily infected than vaccinated hosts but 54 mutations conferring resistance are unlikely to provide a selective advantage in the 55 naïve background. Thus, naïve hosts are likely to shed escape variants at very low, 56 likely, negligible rates. The reverse is true for vaccinated hosts. Recently vaccinated, 57 inoculated, hosts that are not yet immune remain highly susceptible to infection with the 58 originating strain, and in these hosts, mutations conferring resistance are more likely to 59 provide a selective advantage. As a result, a substantial fraction or even most of the 60 virus shed by such hosts will be resistant mutants. This situation is analogous to the 61 administration of a low-dose antibiotic regime^{14,15}. In both cases, the pathogen is 62 introduced to a susceptible host and subject to elevated selective pressure towards the 63 64 emergence of resistant (escape) variants.

65

We sought to establish the constraints imposed by virus escape on optimal vaccine
distribution and the role played by the small, but critical, population of inoculated hosts.
To this end, we constructed an epidemiological compartment model to simulate
vaccination campaigns over a broad parameter regime. This minimally computationally

It is made available under a CC-BY-NC-ND 4.0 International license .

⁷⁰ intensive approach enabled us to simulate many possible scenarios for epidemic

evolution, in order to determine the optimal vaccination strategy for each condition.

72

73 Methods:

74

We divided the population into 7 compartments (Fig. 1A). Three compartments are 75 susceptible to infection by either the originating strain or escape mutants: Naive (N, 76 77 unvaccinated and fully susceptible to the originating strain and escape mutants), Inoculated (*I*, recently vaccinated and still partially susceptible to the originating strain, 78 and fully susceptible to escape mutants), and Vaccinated (V, minimally susceptible to 79 the originating strain, but fully susceptible to escape mutants). Two compartments 80 represent ongoing infection with the originating strain and are distinguished by the 81 host's previous compartment: Infected-Naïve (F) and Infected-Inoculated (M). The third 82 infected compartment represents infection by an escape variant, Infected-Escape (E). 83 The remaining compartment, Recovered (R), contains all hosts who were previously 84 infected. Vaccination is represented by a reduction in susceptibility to infection with the 85 86 originating strain. Naïve hosts are inoculated at rate kv. Inoculated hosts do not immediately acquire immunity and mature into the vaccinated compartment at rate k_{M} . 87 All infected hosts recover at rate k_R . 88

89

Within the timescale of the model, recovery is assumed to grant stable immunity, and 90 any variation in population size due to birth/death is assumed to be negligible. It should 91 be noted that, if recovery from the Infected-Naïve or Infected-Inoculated compartments 92 does not confer immunity against escape infection, the key results in this work will have 93 an even greater impact on the vaccination outcome. Hosts come into contact at rate kc. 94 For simplicity, we assume that contact with an escape-infected host can only produce 95 96 an escape infection. Also, vaccine efficacy is assumed to be perfect such that vaccinated hosts cannot be infected with the originating strain. The Inoculated-Infected 97 compartment is assumed to represent a symmetric composition of escape and 98 originating infections such that the total probability of a Naïve or Inoculated host being 99 infected after contact with a Naïve-Infected or Inoculated-Infected host is the same. 100

It is made available under a CC-BY-NC-ND 4.0 International license .

Finally, we assume that the probability of escape-infection is the same for Naïve and Vaccinated hosts across all three types of infected-susceptible host interactions. This construction yields the following transition probability matrices for Naïve, Inoculated, and Vaccinated hosts:

$$k_{C}P_{N} = k_{I} \begin{bmatrix} 1 & 0 & \alpha \\ 1-\beta & 0 & \alpha+\beta \\ 0 & 0 & \beta \end{bmatrix}; k_{C}P_{I} = k_{I} \begin{bmatrix} 0 & 1+\alpha & 0 \\ 0 & 1+\alpha & 0 \\ 0 & 0 & \beta \end{bmatrix}; k_{C}P_{V} = k_{I} \begin{bmatrix} 0 & 0 & \alpha \\ 0 & 0 & \alpha+\beta \\ 0 & 0 & \beta \end{bmatrix}$$

105

where *k*_l represents the rate of infection for Naïve, Infected-Naïve host interactions
which is determined both by the contact rate *kc* and the infectivity of the originating
strain. Rows represent interaction with each of the infected compartments (InfectedNaïve, Infected-Inoculated, and Infected-Escape). Columns represent transitions to
each of the infected compartments.

111

An escape mutant can emerge within an Infected-Naïve or Infected-Inoculated host. 112 113 The parameter α represents the infectivity of the escape variant relative to the originating strain when a Naïve host interacts with an Infected-Naïve host. The 114 parameter β represents the infectivity of an escape variant when a Naïve host interacts 115 with an Infected-Escape host relative to the infectivity of the originating strain when a 116 Naïve host interacts with an Infected-Naïve host. Informally, α reflects the ratio of 117 escape variant to originating strain shed by Infected-Naïve hosts, whereas β reflects the 118 119 fitness of an escape variant relative to the originating strain. Finally, we introduce the parameter q to represent the impact of varying the rate of host-host contact for 120 Inoculated hosts relative to that for the other compartments. q>1 represents increased 121 contact, and q < 1 corresponds to decreased contact. This completes the model 122 description and structures the differential equations: 123

It is made available under a CC-BY-NC-ND 4.0 International license .

$$N' = -(k_V + k_I ((1 + \alpha) (F + M) + \beta E)) N$$
$$I' = k_V N - (k_M + qk_I ((1 + \alpha) (F + M) + \beta E)) I$$
$$V' = k_M I - k_I (\alpha F + (\alpha + \beta) M + \beta E) V$$
$$F' = k_I (NF + (1 - \beta) NM) - k_R F$$
$$M' = qk_I (1 + \alpha) (F + M) I - k_R M$$
$$E' = k_I ((\alpha F + (\alpha + \beta) M + \beta E) (N + V) + q\beta EI) - k_R E$$
$$R' = k_R (F + M + E)$$

124

 $k_{R}=k_{M}=1/7$ are fixed across all simulations representing a time to recovery and time between inoculation and the acquisition of immunity of one week. Reducing k_{I} would prolong the epidemic and reducing k_{M} would increase the size of the Inoculated compartment.

129

 k_{l} is the principal determinant of epidemic magnitude and duration, with larger k_{l} leading to a greater cumulative number of infections over a shorter period of time (Fig. 1B). However, feedback between the size of the infected population and the rate of host-host contact as well as spatial structure can decouple these variables. Throughout this work, k_{l} is set to a benchmark value of 0.2 resulting in 50% of the population being infected over a period of approximately 4 months.

136

The values of α and β impact the size of the Infected-Escape compartment. Even in the absence of vaccination, large α/β results in the emergence of would-be resistant variants (Fig 1C). In all analyses in this work, α is fixed at the benchmark value of 0.001 resulting in a modest number of would-be resistant infections for β close to 1 in the absence of vaccination. Although a larger α would result in a greater total number of

It is made available under a CC-BY-NC-ND 4.0 International license .

escape infections, the fraction of those infections attributable to contact with inoculatedhosts would be smaller.

144

145 The solutions of the ODEs were obtained using the MATLAB ode45 method¹⁶.

146 Epidemics are simulated until the size of the Recovery compartment at arbitrarily long

147 times is approached. The principal quantity of interest is the cumulative number of

infections. When *kv* is selected to minimize this value, minima are found through explicit

simulation over a range of rates. In the subsequent analysis, some values are

expressed relative to the cumulative number of infections in the absence of vaccination,

151 *R*Null~50%.

152

153 **Results:**

154

155 In addition to the rate of vaccination, the outcome of a vaccination campaign depends on how far the epidemic has progressed before vaccination begins, which can be 156 measured by the relative size of the Recovered compartment. The results also depend 157 on β , informally, the fitness of an escape variant relative to the originating strain. We 158 considered two values for β (0.01, low; 0.875, high) and varied both the start and rate of 159 vaccination. When β is low, that is, the escape mutant is much less fit than the 160 originating strain (Fig. 2A), vaccinating earlier and distributing the vaccine faster 161 162 decreases the cumulative number of infections. If distribution is sufficiently prompt, the cumulative number of infections becomes negligible. 163

164

However, the outcome substantially differs for high β (Fig. 2B). Due to the vaccine 165 escape, at high rates of distribution, the cumulative number of infections remains large. 166 Furthermore, there is an optimal rate of distribution such that exceeding this rate 167 increases the cumulative number of infections. In this regime, the benefit of reducing the 168 size of the population susceptible to infection by the originating strain is outweighed by 169 the cost of increasing the selective pressure for the emergence of escape variants. In all 170 subsequent analysis, the vaccination rate is varied but vaccination is fixed to begin 171 when 1% of the population has recovered from infection. 172

It is made available under a CC-BY-NC-ND 4.0 International license .

173

Infections can be mitigated by reducing host-host contact. We sought to determine how 174 perturbing the contact rates for hosts in the Inoculated compartment relative to that of all 175 other compartments, q, affects the outcome. For β ranging between 0.75 and 1, we 176 considered three relative contact rates, q=[0.2, 1, 5] (Fig. 2C). Increasing the rate of host-177 host contact only within this compartment has a significant impact on the cumulative 178 number of infections. The optimal vaccination rate is also perturbed. Furthermore, if the 179 optimal vaccination rate it exceeded, reducing *q* below 1 slows the accumulation of 180 infections (Fig. 2D). The converse is true for increasing q, and the landscape is similar 181 when vaccination falls below the optimal rate (Fig. 2E). 182

183

Having demonstrated how *q* perturbs the optimal vaccination rate and how reducing *q* 184 below 1 can mitigate or delay the cumulative number of infections even if this rate is not 185 186 met or, conversely, is exceeded, we sought to establish the impact of q on the cumulative number of infections across a wide range of β at the optimal vaccination rate 187 for each condition (Fig. 3A). The cumulative number of infections is sensitive to q across 188 the entire range of β . Varying q within an order of magnitude can substantially aid or 189 hinder the vaccination campaign, and when q >> 1, the optimal rate of vaccination is 0. 190 Note that the maximum vaccination rate considered is kv=0.03 representing the 191 inoculation of 3% of Naïve hosts per day. This rate is sufficiently high that the 192 cumulative number of infections at this rate (Fig. 3B) is similar or higher compared to 193 the hypothetical case where the entire Naïve population is immediately inoculated (Fig. 194 3C). Some of these effects are not specific to the inoculated compartment. Increasing 195 the rate of contact for any arbitrary subpopulation can increase the cumulative number 196 197 of infections. We define the effective k_l, k_leff, such that the cumulative number of infections for $k_{l}=k_{l}eff$ and q=1 is equal to the cumulative number of infections for $k_{l}=0.2$ 198 (the benchmark) and arbitrary q. Increasing q within an order of magnitude is equivalent 199 to substantially increasing k for the entire population for the entirety of the epidemic 200 (Fig. 3D). 201

202

It is made available under a CC-BY-NC-ND 4.0 International license .

We additionally consider the cumulative infections added or subtracted relative to the outcome corresponding to q=1 and scaled by the fraction of infections due to vaccine escape (Fig. 3E). Varying q within an order of magnitude alters the cumulative number of infections added or subtracted by more than 20% of the cumulative number of infections in the absence of vaccination, *R*_{Null}, again demonstrating the critical role played by inoculated hosts with respect to vaccine escape. The landscape is similar when then rate of vaccination is fixed (Fig. 3F).

210

211 **Discussion:**

212

Epidemics can be mitigated through the reduction of host-host contact (guarantines and 213 214 other similar measures) and vaccination. A reduction in contact carries non-negligible social and economic burdens so that, when vaccination becomes possible, the 215 216 continuation of such interventions might appear unnecessarily costly. Formulating an optimal vaccination strategy to balance these pressures is challenging and is further 217 complicated by the possibility of vaccine escape. Escape variants emergingas a result 218 of vaccination are not expected to be more infectious than the originating strain, 219 otherwise, such variants would likely already be in circulation prior to vaccination. 220 However, newly emergent variants are not always much less infectious and can be 221 responsible for non-negligible disease incidence^{17,18}. Here, we demonstrated that, even 222 223 when escape variants are modestly less infectious, there exists an optimal vaccination distribution rate such that exceeding this rate increases the cumulative number of 224 infections. This optimal rate depends on the infectivity of the escape variants. Such a 225 prediction is impractical at the time of writing, that is, in the very first days of the 226 vaccination campaign, and the cost of overestimation of the optimal vaccination rate is 227 far less than that of underestimation. However, to our knowledge, this phenomenon, 228 analogous to the evolution of antibiotic resistance, is not widely appreciated and, as 229 such, seems to warrant discussion. 230

231

Of more practical concern is the role of inoculated hosts in the emergence of escape variants. Within low-dose antibiotic regimes ^{14,15}, hosts are susceptible to infection with

It is made available under a CC-BY-NC-ND 4.0 International license .

the originating variant, and in such hosts, the pathogen is subjected to elevated 234 selective pressures towards the emergence of resistance. Similarly, within inoculated 235 hosts, the virus is subjected to gradually increasing selective pressures towards the 236 emergence of resistance while the intra-host population remains sufficiently large to 237 explore a substantial fraction of the mutation space. We demonstrated that moderately 238 increasing or decreasing the host-host contact rates for inoculated hosts only can 239 substantially aid or hinder the vaccination campaign. The time between vaccination and 240 the acquisition of immunity can be readily approximated from clinical endpoints^{19,20} and 241 is likely to be short enough that the societal costs of limiting post-vaccination contact 242 would be outweighed by these benefits. 243

244

245 **Limitations:**

246

In this study, we leveraged classical modelling techniques to elucidate the factors that could substantially impact the outcome of any vaccination campaign. Although these results are broadly applicable, they are not necessarily instrumental for predicting quantitative outcomes for the current SARS-CoV-2 pandemic or any other particular epidemic. Similarly, the model presented in this study is not designed to forecast longterm outcome, a topic that has been thoroughly addressed for the case of SARS-Cov-2 and more generally^{7-13,21-23}.

254

The results presented here appear to be of immediate interest in relation to the vaccination campaign against SARS-Cov-2 that is beginning at the time of this writing. However, although diversification of the virus is apparent²⁴⁻²⁶ and the potential for escape is being actively investigated^{5,6,27,28}, it cannot be ruled out that all escape variants have a substantially reduced infectivity, represented by $\beta <<1$, in which case the highest possible vaccination rate will be optimal and the benefits specific to postvaccination contact limitation could be negligible.

262

263 **Conclusions:**

It is made available under a CC-BY-NC-ND 4.0 International license .

Depending on the infectivity of escaping, vaccine-resistant mutants, the optimal 265 vaccination rate with respect to the cumulative number of infections can be lower than 266 the maximum rate. Contact rates for inoculated hosts can have a substantial impact on 267 the outcomes of vaccination campaigns. Even a brief and moderate limitation of 268 contacts in this well-defined population can potentially mitigate epidemics. These results 269 might merit consideration for an immediate, practical public health response. 270 271 **Author Contributions:** 272 273 NDR, YIW, and EVK conceived of the study; NDR constructed the model; NDR, YIW, 274 and EVK analyzed data; NDR and EVK wrote the manuscript that was edited and 275 276 approved by all authors. 277 Acknowledgements: 278 279 280 The authors thank Koonin group members for helpful discussions. NDR, YIW, and EVK are supported by the Intramural Research Program of the National Institutes of Health 281 (National Library of Medicine). 282 283

It is made available under a CC-BY-NC-ND 4.0 International license .

284 References:

200	
286	1. CDC. Public Health Guidance for Potential COVID-19 Exposure Associated with Travel. 2020.
287	2. Neumann-Böhme S, Varghese NE, Sabat I, et al. Once we have it, will we use it? A European survey on
288	willingness to be vaccinated against COVID-19. The European Journal of Health Economics: Springer; 2020.
289	3. Quinn SC, Kumar S, Freimuth VS, Kidwell K, Musa D. Public willingness to take a vaccine or drug under
290	Emergency Use Authorization during the 2009 H1N1 pandemic. <i>Biosecurity and Bioterrorism : Biodefense Strategy,</i>
291	Practice, and Science 2009; 7 (3): 275-90.
291	 Mills MC, Salisbury D. The challenges of distributing COVID-19 vaccinations. <i>EClinicalMedicine</i> 2020.
292	, , ,
294	<i>Cell</i> 2020; 182 (5): 1284-94. e9.
295	6. Kennedy DA, Read AF. Monitor for COVID-19 vaccine resistance evolution during clinical trials. <i>PLoS</i>
296	Biology 2020; 18 (11): e3001000.
297	7. Magpantay F, King A, Rohani P. Age-structure and transient dynamics in epidemiological systems. <i>Journal</i>
298	of the Royal Society Interface 2019; 16 (156): 20190151.
299	8. Restif O, Grenfell BT. Integrating life history and cross-immunity into the evolutionary dynamics of
300	pathogens. Proceedings of the Royal Society B: Biological Sciences 2006; 273 (1585): 409-16.
301	9. Rodrigues HS, Monteiro MTT, Torres DF. Vaccination models and optimal control strategies to dengue.
302	Mathematical biosciences 2014; 247 : 1-12.
303	10. Safan M, Kretzschmar M, Hadeler KP. Vaccination based control of infections in SIRS models with
304	reinfection: special reference to pertussis. <i>Journal of mathematical biolog</i> y 2013; 67 (5): 1083-110.
305	11. Scherer A, McLean A. Mathematical models of vaccination. <i>British Medical Bulletin</i> 2002; 62 (1): 187-99.
306	12. van Boven M, Mooi FR, Schellekens JF, de Melker HE, Kretzschmar M. Pathogen adaptation under
307	imperfect vaccination: implications for pertussis. Proceedings of the Royal Society B: Biological Sciences 2005;
308	272 (1572): 1617-24.
309	13. Gandon S, Day T. The evolutionary epidemiology of vaccination. <i>Journal of the Royal Society Interface</i>
310	2007; 4 (16): 803-17.
311	14. Livermore DM. Minimising antibiotic resistance. <i>The Lancet infectious diseases</i> 2005; 5 (7): 450-9.
312	15. Roberts JA, Kruger P, Paterson DL, Lipman J. Antibiotic resistance—what's dosing got to do with it? <i>Critical</i>
313	care medicine 2008; 36 (8): 2433-40.
314	16. Shampine LF, Reichelt MW. The matlab ode suite. <i>SIAM journal on scientific computing</i> 1997; 18 (1): 1-22.
315	17. Carman WF, Karayiannis P, Waters J, et al. Vaccine-induced escape mutant of hepatitis B virus. <i>The Lancet</i>
316	1990; 336 (8711): 325-9.
317	18. Brueggemann AB, Pai R, Crook DW, Beall B. Vaccine escape recombinants emerge after pneumococcal
318	vaccination in the United States. <i>PLoS Pathog</i> 2007; 3 (11): e168.
319	19. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. <i>New</i>
320	England Journal of Medicine 2020.
321	20. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2
322	vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical
323	trial. The Lancet Infectious Diseases 2020.
324	21. Saad-Roy CM, Wagner CE, Baker RE, et al. Immune life history, vaccination, and the dynamics of SARS-
324	CoV-2 over the next 5 years. <i>Science</i> 2020; 370 (6518): 811-8.
326 327	 Day T, Gandon S, Lion S, Otto SP. On the evolutionary epidemiology of SARS-CoV-2. <i>Current Biology</i> 2020. Rochman ND, Wolf YI, Koonin EV. Evolution of Human Respiratory Virus Epidemics. <i>medRxiv</i> 2020:
328	2020.11.23.20237503.
329	24. Kumar S, Tao Q, Weaver S, et al. An evolutionary portrait of the progenitor SARS-CoV-2 and its dominant
330	offshoots in COVID-19 pandemic. <i>bioRxiv</i> 2020.
331	25. Rochman ND, Wolf YI, Faure G, Zhang F, Koonin EV. Ongoing Global and Regional Adaptive Evolution of
332	SARS-CoV-2. bioRxiv 2020.
333	26. van Dorp L, Acman M, Richard D, et al. Emergence of genomic diversity and recurrent mutations in SARS-
334	CoV-2. Infection, Genetics, Evolution 2020: 104351.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 335 27. Garrett ME, Galloway J, Chu HY, et al. High resolution profiling of pathways of escape for SARS-CoV-2
- 336 spike-binding antibodies. *bioRxiv* 2020.
- 28. Starr TN, Greaney AJ, Hilton SK, et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain
- reveals constraints on folding and ACE2 binding. *Cell* 2020; **182**(5): 1295-310. e20.

339

It is made available under a CC-BY-NC-ND 4.0 International license .

341

342 Figure legends

343

Figure 1. The Model. A. Schematic of the 7 compartment model with three susceptible, three infected, and one recovered compartments. **B.** Simulated epidemics for $k_{I}=[0.15, 0.175, 0.2(\text{solid line}), 0.225, 0.25], \alpha=0.001, \beta=0.01$ **C.** The ratio of cumulative escape infections to all cumulative infections for an epidemic over a range of α . $\beta=[0.5, 0.67, 0.83, 1], \text{ darker color indicates higher value, } k_{I}=0.2$. The dotted line specifies

- the benchmark value of α =0.001.
- 350

Figure 2. Optimal Vaccine Distribution. A. The cumulative number of infections 351 352 relative to no vaccination, RNull, for a range of vaccine initiations and distribution rates. Here β is low, 0.01. **B.** The cumulative number of infections relative to no vaccination, 353 354 *R*_{Null}, for a range of vaccine initiations and distribution rates and a large β (0.875). **A/B**. 3840 values were computed for each panel and 4x by 4x bilinearly interpolated points 355 are displayed. C. The cumulative number of infections relative to no vaccination, RNull, 356 for $\beta = [0.75 (\text{dotted}), 0.875 (\text{dashed}), 1 (\text{solid})]$ and three relative contact rates, 357 q=[0.2(brown), 1(black), 5(gray)]. **D.** Simulated epidemics comparing a high fixed rate of 358 vaccination, kv=0.03 (solid) representing the inoculation of 3% of Naïve hosts per day, 359 and the optimal vaccination rate for each condition (dashed). $\beta = 0.875$ is fixed and 360 q=[0.2(brown), 1(black), 5(gray)]. E. Same as D. with a low fixed rate of vaccination, 361 kv=0.01. C/D/E. The minima for the dashed lines in C correspond to the dashed lines in 362 D/E. 363

364

Figure 3. Post-vaccination contacts. A. The cumulative number of infections relative to no vaccination, *R*_{Null}, for a range of β and q, optimizing *kv* for each condition. B. Same as in A. for fixed *kv=0.03* representing the inoculation of 3% of Naïve hosts per day. C. Same as in A. for the case where all Naïve hosts are immediately inoculated. D. Log of the effective *k*_l, *k*_l*eff*, relative to *k*_l=0.2, the benchmark, vs. log of *q* for β =[0.5 (dotted line), 0.7 (dashed line), 1 (solid line)]. E. The cumulative number of infections relative to *R*_{Null} and *q*=1 scaled by the fraction of infections due to vaccine escape.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 372 $\sum \text{Escape}(q) / \sum \text{Infections}(q) (\sum \text{Infections}(q) \sum \text{Infections}(q=1)) / \text{R}_{\text{Null}}$, for a range of β and q,
- optimizing kv for each condition. **F.** Same as in E for fixed kv=0.03. **A-C/E/F.** 961 values
- were computed for each panel and 4x by 4x bilinearly interpolated points are displayed.





